标题
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
作者
关键词
-
出版物
DRUGS
Volume 78, Issue 18, Pages 1903-1910
出版商
Springer Nature
发表日期
2018-12-03
DOI
10.1007/s40265-018-1022-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Burden of Acute Myeloid Leukemia Among Older, Newly Diagnosed Patients: Retrospective Analysis of Data From the 2010–2012 Medicare Limited Data Set
- (2018) Naomi C. Sacks et al. CLINICAL THERAPEUTICS
- Improving combination cancer therapy: the CombiPlex® development platform
- (2018) Anthony W Tolcher et al. Future Oncology
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- CPX-351 for the Treatment of Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (TAML) or AML with Myelodysplasia-Related Changes (AML-MRC): An Analysis of Clinical Benefit
- (2018) KC Chung et al. VALUE IN HEALTH
- Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
- (2018) Evan C Chen et al. OncoTargets and Therapy
- Scavenger receptor class BI (SR-BI) mediates uptake of CPX-351 into K562 leukemia cells
- (2018) Yunyun Di et al. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
- Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia
- (2018) May Hagiwara et al. JOURNAL OF MEDICAL ECONOMICS
- CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation
- (2017) Max J. Gordon et al. LEUKEMIA RESEARCH
- Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study
- (2015) Lene Sofie Granfeldt Østgård et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
- (2014) J. E. Lancet et al. BLOOD
- Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML
- (2014) Jorge E. Cortes et al. CANCER
- Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia
- (2012) E.J. Feldman et al. LEUKEMIA RESEARCH
- Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells
- (2011) Hyun Pyo Kim et al. EXPERIMENTAL HEMATOLOGY
- First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
- (2011) Eric J. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
- (2010) S. Kayser et al. BLOOD
- Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin
- (2010) Awa Dicko et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts
- (2010) Wah-Seng Lim et al. LEUKEMIA RESEARCH
- In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy
- (2008) Paul Tardi et al. LEUKEMIA RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started